Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971210 | 0.84 | EPHX1 (0.44) | SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL1762876 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| Hydrochloric Acid SCHEMBL3579455 | 0.82 | EPHX1 (0.50) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| SCHEMBL4822849 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2EPHX1EPHX2HSD11B1HRH3 | |
| SCHEMBL8971215 | 0.80 | GNAO1 (0.50) | EPHX1EPHX2 | |
| SCHEMBL23945762 | 0.79 | PIK3CD (0.52) | SMN1; SMN2EPHX1AKR1C3HRH3 | |
| SCHEMBL16978124 | 0.79 | EPHX1 (0.48) | SMN1; SMN2EPHX1EPHX2HSD11B1HRH3 | |
| SCHEMBL11916766 | 0.79 | EPHX1 (0.51) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| SCHEMBL14155747 | 0.79 | EPHX1 (0.48) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| SCHEMBL25122872 | 0.79 | EPHX1 (0.48) | SMN1; SMN2EPHX1EPHX2HSD11B1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | SMN1; SMN2 2399/4885EPHX1 2991/4885EPHX2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.